There are provided, inter alia, methods for reacting an enzyme and its substrate, methods for purifying a protein and an enzyme reactor and its use thereof.

This invention belongs to the field of preparation of macromolecule sample of various volumes, pertaining to a detergent-mixed dry hydrogel particle and a method of using the particle to mass concentrate the macromolecule liquid sample or to enhance specific activity of the protein liquid sample. After thorough suspension and hydration in a detergent solution, the hydrogel particle is separated from the excess of the detergent solution and dried into the detergent-mixed dry hydrogel particle; upon contacting the macromolecule liquid sample in certain ratio with the dry particle having a pore size of its cross-linked network smaller than the macromolecule to allow absorption and swelling of the hydrogel particle, filter centrifugation or filter conical rotating drum centrifugation is exercised to remove the hydrogel particle whose surface is deprived of water and to collect the concentrate filtrate of the macromolecule mass or the protein sample with enhanced specific activity.

A detoxification method includes the steps of inducing flow of patient blood through an extracorporeal device inlet and outlet in fluid connection to the circulatory system of a patient. Biological agents including lipopolysaccharide (LPS) contained within patient blood can be detoxified by passing patient blood over a biochemical reactor surface having attached or immobilized Saccharomyces boulardii alkaline phosphatase enzyme, with the biochemical reactor being contained within the extracorporeal device. An acyloxyacyl hydrolase enzyme may also be used on the biochemical reactor surface.

The present invention relates to the use of a substrate for enhancing the chemiluminescence of one or more luminophores produced in a chemiluminescence reaction, wherein the substrate comprises a solid polymeric carrier with a plurality of depressions separated from one another and that the solid carrier is at least partially coated with a metal.

A composition contains an alkaline phosphatase; and a peptide fragment group (A) composed of two or more peptide fragments, wherein each of the two or more peptide fragments consists of 5 to 50 consecutive amino acid residues selected from positions 501 to 578 of the amino acid sequence set forth in SEQ ID NO: 5, wherein a content ratio of the peptide fragment group (A) to the alkaline phosphatase satisfies formula (A): (X.sub.A/Y)×100≤4.4000 (A), wherein X.sub.A represents a peak area value of the peptide fragment group (A) calculated by an automatic integration method from an extracted ion chromatogram obtained by an LC-MS/MS analysis of the composition, and Y represents a peak area value of the alkaline phosphatase calculated by an automatic integration method from a chromatogram obtained by an LC-UV analysis of the composition.

A method of producing recombinant alkaline phosphatase comprising control of production parameters, particularly harvest clarified culture fluid (HCCF) and filtration pool (UFDF), to provide a defined total sialic acid content.

Present invention relates to a composition for use in the treatment of arthritides. Alkaline phosphatase (AP), an ectophosphatase with an anti-inflammatory and barrier protecting mechanism of action shows potent anti-rheumatoid arthritis (anti-RA) efficacy in a rat model for arthritis. In this model RA was induced by subcutaneous immunization with a mixture of methylated bovine serum albumin (mBSA), CFA (complete Freund's adjuvant antigen) and CBP (custom Bordetella pertussis antigen) and intra-articular injections of mBSA. Results were comparable with those obtained for MTX, the drug reference compound for the treatment of RA. Both knee swelling over time and the number of invading macrophages were found to be reduced with AP treatment, either applied in prophylactic treatment or therapeutic treatment, and comparable to the MTX effects. AP was found effective both as prophylactic, and as therapeutic intervention. Altogether, ectophosphatase intervention by AP fulfills a novel and unmet niche in RA treatment by combining different, yet synergistic mode of actions with MTX.

Described herein are biological devices and methods for using the same to produce oxidized zinc. The biological devices include microbial cells transformed with a DNA construct containing genes for producing a zinc-related protein, an alkaline phosphatase, and an alcohol dehydrogenase. In some instances, the biological devices also include a gene for lipase. The oxidized zinc compositions produced herein have numerous applications.

The disclosure features methods for treating tracheobronchomalacia (TBM) in a patient having hypophosphatasia (HPP), such as an infant, by administering a soluble alkaline phosphatase (sALP) to the patient.

The present invention relates to a biomarker and target for diagnosis, prognosis and treatment of ankylosing spondylitis (AS). The present invention also relates to a method for producing an animal model for AS, an animal model produced therefrom, and a method for screening for an agent pharmaceutically active in the treatment of A S using such animal model.